Abstract
Fibromyalgia (FM) is a prevalent syndrome with chronic pain and a hypothesised underlying disturbance of the tryptophan (TRP) metabolism. We performed a tryptophan depletion (TD) test in 17 FM patients and 17 controls. TRP, 5-hydroxyindoleacetic acid (5-HIAA), kynurenine (KYN), and Interleukin-6 (IL-6) were measured. Additionally pain perception was monitored in the FM patients. FM patients and controls exhibited a decrease of TRP and KYN during TD. 5-HIAA levels also decreased in all controls and in 11 FM patients, but showed a marked increase in 6 FM patients. IL-6 significantly increased during TD in the patients, but not in the controls. Pain perception was not affected in the FM patients. These data demonstrate an altered TRP metabolism in a subgroup of FM patients, where the TD seems to activate 5-HT metabolism and IL-6 production. Our findings may have diagnostic as well as therapeutic implications in the field of fibromyalgia.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
F. Wolfe, H.A. Smythe, M.B. Yunus, R.M. Bennett, C. Bombardier, D.L. Goldenberg, P. Tugwell, S.M. Campbell, M. Abeles, P. Clark, A.G. Fam, S..I. Farber, J.J. Fiechtner, C.M. Franklin, R.A. Garter. D. Hamaty, J. Lessrad, A.S. Lichtbroun, A.T. Masi, G.A. McCain, W.J.Reynolds, T.J. Romano, I.J.Russell, and R.P. Sheon, The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee [see comments]Arthritis.Rheum 33160Â-172 (1990)
F. Wolfe, K. Ross, J. Anderson, and I.J. Russell, Aspects of fibromyalgia in the general population: sex, pain threshold, and fibromyalgia symptomsJ. Rheumatol.22, 151–156 (1995).
F. Wolfe, K. Ross, J. Anderson, I.J. Russell, and L. Hebert, The prevalence and characteristics of fibromyalgia in the general populationArthritis. Rheum. 3819–28 (1995).
R.S. Katz and H.M. Kravitz, Fibromyalgia, depression, and alcoholism: a family history studyJ. Rheumatol. 23149–154 (1996).
J.I. Hudson, D.L. Goldenberg, H.G. Pope, P.E. Keck, and L. Schlesinger, Comorbidity of fibromyalgia with medical and psychiatric disordersAm.J.Med. 92363–367 (1992).
M. Offenbächer, K. Glatzeder, and M. Ackenheil, Self reported depression, familial history of depression and fibromyalgia (FM) and psychological distress in patients with FMZ.Rheumatol. 5794–96 (1998).
J.I. Hudson and H.G. Pope. The relationship between fibromyalgia and major depressive disorderRheum. Dis. Clin. North Am. 22285–303 (1996).
L.M. Arnold, P.E. Keck, and J.A. Welge, Antidepressant treatment of fibromyalgia. A meta-analysis and reviewPsychosomatics 41104–113 (2000).
D. Fishbain, Evidence-based data on pain relief with antidepressantsAnn. Med. 32305–316 (2000).
H. Moldofsky, Rheumatic pain modulation syndrome: the interrelationships between sleep, central nervous system serotonin, and painAdv. Neurol. 3351–57 (1982).
F. WolfeI.J.Russell, G. Vipraio, K. Ross, and J. Anderson, Serotonin levels, pain threshold, and fibromyalgia symptoms in the general populationJ. Rheumatol. 24555–559 (1997).
T. Stratz, W. Samborski, P. Hrycaj, T. Pap, S. Mackiewicz, P. Mennet, and W. Muller, Serotonin concentration in serum of patients with generalized tendomyopathy (fibromyalgia) and chronic polyarthritisMed. Klin. 88458–462 (1993).
I.J. Russell, H. Vaeroy, M. Javors, and F. Nyberg, Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis [see comments]Arthritis.Rheum. 35550–556 (1992).
I.1. Russell, Neurochemical Pathogenesis of Fibromyalgia SyndromeJ. Musculoscheletal Pain4, 61–92 (1996).
I.J. Russell, J.E. Michalek, G.A. Vipraio, E.M. Fletcher, M.A. Javors, and C.A. Bowden, Platelet 3HÂimipramine uptake receptor density and serum serotonin levels in patients with fibromyalgia/fibrositis syndrome [see comments]J. Rheumatol. 19104–109 (1992).
M.J. Schwarz, Spaeth M., Müller-Bardorff H., Pongratz D., Bondy B., and M. Ackenheil Relationship of Substance P, 5-Hydroxyindoleacetic Acid and Tryptophan in Serum of Fibromyalgia PatientsNeurosci. Lett. 259196–198 (1999).
G. Neeck and W. Riedel, Neuromediator and hormonal perturbations in fibromyalgia syndrome: results of chronic stress?Baillieres Clin. Rheumatol. 8763–775 (1994).
A. Heils, A. Teufel, S. Petri, G. Stober, P. Riederer, D. Bengel, and K.P. Lesch, Allelic variation of human serotonin transporter gene expressionJ. Neuroche m. 662621–2624 (1996).
P.K. Eide and K. Hole, Interactions between serotonin and substance P in the spinal regulation of nociceptionBrain Res.550, 225–230 (1991).
W.M. Pardridge, Blood-brain barrier carrier-mediated transport and brain metabolism of amino acidsNeurochem. Res.23, 635–644 (1998).
A. Frazer and J.G. Hensler, Serotonin, in:Basic Neurochemistryedited by G. J. Siegel, B. W. Agranoff, R. W. Albers, S. K. Fisher, & M. D. Uhler, 6 edition (Lippincott-Raven Publishers, Philadelphia, 1999), pp. 263–292.
M.W. Taylor and G.S. Feng, Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolismFASEB J. 52516–2522 (1991).
R.R. Brown, Y. Ozaki, S.P. Datta, E.C. Borden, P.M. Sondel, and D.G. Malone, Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDSAdv. Exp. Med. Biol. 294425Â-435 (1991).
R. Stancampiano, F. Melis, L. Sarais, S. Cocco, C. Cugusi, and F. Fadda, Acute administration of a tryptophan-free amino acid mixture decreases 5–1-IT release in rat hippocampus in vivoAm. J. Physiol272, R991–R994 (1997).
G. Biggio, F. Fadda, P. Fanni, A. Tagliamonte, and G.L. Gessa, Rapid depletion of serum tryptophan, brain tryptophan, serotonin and 5-hydroxyindoleacetic acid by a tryptophan-free dietLife Sci.14, 1321–1329 (1974).
G.L. Gessa, G. Biggio, F. Fadda, G.U. Corsini, and A. Tagliamonte, Tryptophan-free diet: a new means for rapidly decreasing brain tryptophan content and serotonin synthesisActa Vitaminol. Enzymol. 2972–78 (1975).
S.N. Young, S.E. Smith, R.O. Pihl, and F.R. Ervin, Tryptophan depletion causes a rapid lowering of mood in normal malesPsychopharmacology (Berl) 87173–177 (1985).
C. Benkelfat, M.A. Ellenbogen, P. Dean, R.M. Palmour, and S.N. Young, Mood-lowering effect of tryptophan depletion. Enhanced susceptibility in young men at genetic risk for major affective disordersArch. Gen. Psychiatry 51687–697 (1994).
W.A. Williams, S.E. Shoaf, D. Hommer, R. Rawlings, and M. Linnoila, Effects of acute tryptophan depletion on plasma and cerebrospinal fluid tryptophan and 5-hydroxyindoleacetic acid in normal volunteersJ. Neurochem.72, 1641–1647 (1999).
M.P. Heyes, C.Y. Chen, E.O. Major, and K. Saito, Different kynurenine pathway enzymes limit quinolinic acid formation by various human cell types.Biochem.J. 326351–356 (1997).
C. Huber, J.R. Batchelor, D. Fuchs, A. Hausen, A. Lang, D. Niederwieser, G. Reibnegger, P. Swetly, J. Troppmair, and H. Wachter, Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gammaJ. Exp. Med. 160310–316 (1984).
A.A. Beharka, M. Meydani, D. Wu, L.S. Leka, A. Meydani, and S.N. Meydani, lnterleukin-6 production does not increase with ageJ. Geroniol. A Biol. Sci. Med. Sci. 56B81–B88 (2001).
P.L. Delgado, D.S. Chamey, L.H. Price, G.K. Aghajanian, H. Landis, and G.R. Heninger, Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophanArch.Gen.Psychiatry 47411–418 (1990).
C. Bell, J. Abrams, and D. Nutt, Tryptophan depletion and its implications for psychiatryBr. J. Psychiatry . 178399–405 (2001).
D.L. Murphy, I.C. Campbell, and J.L. Costa, The brain serotonergic system in the affective disordersProg. Neuropsychopharmacol. 25–31 (1978).
H.Y. Meltzer, Role of serotonin in depressionAnn. N. Y. Acad. Sci.600, 486–499 (1990).
J.D. Bremner, R.B. Innis, R.M. Salomon, L.H. Staib, C.K. Ng, H.L. Miller, R.A. Bronen, J.H. Krystal, J. Duncan, D. Rich, L.H. Price, R. Malison, H. Dey, R. Soufer, and D.S. Chamey, Positron emission tomography measurement of cerebral metabolic correlates of tryptophan depletion-induced depressive relapseArch. Gen. Psychiatry 54364–374 (1997).
A. Neumeister, N. Praschak-Rieder, B. Besselmann, M.L. Rao, J. Gluck, and S. Kasper, Effects of tryptophan depletion on drug-free patients with seasonal affective disorder during a stable response to bright light therapyArch. Gen. Psychiatry 54133–138 (1997).
L.L. Carpenter, G.M. Anderson, G.H. Pelton, J.A. Gudin, P.D. Kirwin, L.H. Price, G.R. Heninger, and C.J. McDougle, Tryptophan depletion during continuous CSF sampling in healthy human subjects.Neuropsychopharmacology 1926–35 (1998).
A.V. Ravindran, J. Griffiths, Z. Merali, V.J. Knott, and H. Anisman, Influence of acute tryptophan depletion on mood and immune measures in healthy malesPsychoneuroendocrinology 2499–1I3 (1999).
M. Maes, R. Verkerk, L. Delmeire, A. Van Gastel, F. van Hunsel, and S. Scharpe, Serotonergic markers and lowered plasma branched-chain-amino acid concentrations in fibromyalgiaPsychiatry Res. 9711–20 (2000).
F.V. Abbott, P. Etienne, K.B. Franklin, M.J. Morgan, M.J. Sewitch, and S.N. Young, Acute tryptophan depletion blocks morphine analgesia in the cold-pressor test in humansPsychopharmacology (Berl) 10860–66 (1992).
F.A. Moreno, C. McGavin, T.P. Malan, 00C1.J. Gelenberg, G.R. Heninger, A.A. Mathe, and P.L. Delgado, Tryptophan depletion selectively reduces CSF 5-HT metabolites in healthy young men: results from single lumbar puncture sampling techniqueInt. J. Neuropsychopharmacol. 3277–283 (2000).
S. Bonaccorso, A.H. Lin, R. Verkerk, F. van Hunsel, I. Libbrecht, S. Scharpe, L. DeClerck, M. Biondi, A. Janca, and M. Maes, Immune markers in fibromyalgia: comparison with major depressed patients and normal volunteersJ. Affect. Disord. 4875–82 (1998).
B. Widner, F. Leblhuber, J. Walli, G.P. Tilz, U. Demel, and D. Fuchs, Degradation of tryptophan in neurodegenerative disordersAdv. Exp. Med. Biol. 467133–138 (1999).
M. Maes, S. Scharpe, H.Y. Meltzer, G. Okayli, E. Bosmans, P. D’Hondt, B.V. Vanden Bossche, and P. Cosyns, Increased neopterin and interferon-gamma secretion and lower availability of L-tryptophan in major depression: further evidence for an immune responsePsychiatry Res. 54143–160 (1994).
J. Wang and A.J. Dunn, The role of interleukin-6 in the activation of the hypothalamo-pituitaryÂadrenocortical axis and brain indoleamines by endotoxin and interleukin-1 betaBrain Res. 815337–348 (1999).
J. Wang and A.J. Dunn, Mouse interleukin-6 stimulates the HPA axis and increases brain tryptophan and serotonin metabolismNeurochem. Int. 33143–154 (1998).
S. Zalcman, J.M. Green-Johnson, L. Murray, D.M. Nance, D. Dyck, H. Anisman, andA.H.Greenberg, Cytokine-specific central monoamine alterations induced by interleukin-I, -2 and —6Brain Res. 64340Â-49 (1994).
N. Barkhudaryan and A.J. Dunn, Molecular mechanisms of actions of interleukin-6 on the brain, with special reference to serotonin and the hypothalamo-pituitary-adrenocortical axisNeurochem. Res. 24.1169–1180 (1999).
W. Allaerts, P.H. Jeucken, R. Debets, S. Hoefakker, E. Claassen, and H.A. Drexhage, Heterogeneity of pituitary folliculo-stellate cells: implications for interleukin-6 production and accessory function in vitroJ. Neuroendocrinol. 943–53 (1997).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer Science+Business Media New York
About this chapter
Cite this chapter
Schwarz, M., Offenbaecher, M., Neumeister, A., Ackenheil, M. (2003). Experimental Evaluation of an Altered Tryptophan Metabolism in Fibromyalgia. In: Allegri, G., Costa, C.V.L., Ragazzi, E., Steinhart, H., Varesio, L. (eds) Developments in Tryptophan and Serotonin Metabolism. Advances in Experimental Medicine and Biology, vol 527. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-0135-0_30
Download citation
DOI: https://doi.org/10.1007/978-1-4615-0135-0_30
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-4939-6
Online ISBN: 978-1-4615-0135-0
eBook Packages: Springer Book Archive